NCT04397523View on ClinicalTrials.gov

Efficacy and Safety of COVID-19 Convalescent Plasma

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

May 10, 2021

Study Completion Date

May 10, 2021

Conditions
Convalescent PlasmaCOVID-19SARS-CoV 2
Interventions
BIOLOGICAL

anti-SARS-CoV-2 convalescent plasma

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Trial Locations (1)

1000

Institute for Transfusion Medicine of RNM, Skopje

All Listed Sponsors
collaborator

University Clinic for Infectious Diseases, North Macedonia

OTHER

lead

Institute for Transfusion Medicine of RNM

OTHER_GOV

NCT04397523 - Efficacy and Safety of COVID-19 Convalescent Plasma | Biotech Hunter | Biotech Hunter